Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current study investigated the effects of short-term (4-week) streptozotocin (STZ)-induced diabetes on responses mediated by endothelium-derived contracting factors (EDCFs) as well as possible contributions of Rho-kinase and AMP-activated kinase (AMPK) signaling pathways.
|
30785783 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
AMP, 5-Aminoimidazole-4-carboxamide riboside (AICA riboside) and A769662 are important activators of AMPK which have potential therapeutic importance in diabetes and diabetic complications.
|
29623826 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
AMP deaminase deficient subjects experience some negative effects like decreased muscle power output, but also positive effects such as decreased diabetes and improved prognosis for chronic heart failure patients.
|
30837873 |
2019 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neprilysin inhibitors may also be able to augment the effects of long-acting GLP-1 analogues to increase heart rate and myocardial cyclic AMP, and thus, potentiate these deleterious actions; if so, concomitant treatment with GLP-1 receptor agonists may limit the efficacy of neprilysin inhibitors in patients with both heart failure and diabetes.
|
29603541 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metformin (MET) is a diabetes drug that activates AMP-activated protein kinase (AMPK), and is suggested to have anticancer efficacy.
|
30334324 |
2018 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Metallothionein can modulate various stress-induced signaling pathways (mitogen-activated protein kinase, Wnt, nuclear factor-κB, phosphatidylinositol 3-kinase, sirtuin 1/AMP-activated protein kinase and fibroblast growth factor 21) to alleviate diabetes and diabetic complications.
|
29072367 |
2018 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ergostatrien-3β-ol from Antrodia camphorata inhibits diabetes and hyperlipidemia in high-fat-diet treated mice via regulation of hepatic related genes, glucose transporter 4, and AMP-activated protein kinase phosphorylation.
|
25693659 |
2015 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids.
|
24755741 |
2014 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the category of "Top Molecules" up-regulated, both venom and Byetta(®) shared IL-8, cyclic AMP-dependent transcription factor 3 (ATF-3), neuron-derived orphan receptor 1 (NR4A3), dexamethasone-induced Ras-related protein 1 (RASD1) and early growth response protein 1, (EGR-1) all with potential relevance in diabetes.
|
23602926 |
2013 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The iminosugar N-(5'-adamantane-1'-yl-methoxy)-pentyl-1-deoxynoijirimycin (AMP-DNM), an inhibitor of glycosphingolipid (GSL) biosynthesis is known to ameliorate diabetes, insulin sensitivity and to prevent liver steatosis in ob/ob mice.
|
23056165 |
2012 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes.
|
19652946 |
2009 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I.
|
19528375 |
2009 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes.
|
18369362 |
2008 |